期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 172, 期 8, 页码 1961-1973出版社
WILEY
DOI: 10.1111/bph.13064
关键词
-
资金
- National Institutes of Health [NIH-HL072684]
The development of novel adjuvant strategies capable of attenuating myocardial ischaemia-reperfusion injury and reducing infarct size remains a major, unmet clinical need. A wealth of preclinical evidence has established that ischaemic conditioning' is profoundly cardioprotective, and has positioned the phenomenon (in particular, the paradigms of postconditioning and remote conditioning) as the most promising and potent candidate for clinical translation identified to date. However, despite this preclinical consensus, current phase II trials have been plagued by heterogeneity, and the outcomes of recent meta-analyses have largely failed to confirm significant benefit. As a result, the path to clinical application has been perceived as disappointing' and frustrating'. The goal of the current review is to discuss the pitfalls that may be stalling the successful clinical translation of ischaemic conditioning, with an emphasis on concerns regarding: (i) appropriate clinical study design and (ii) the choice of the right' preclinical models to facilitate clinical translation. Linked ArticlesThis article is part of a themed section on Conditioning the Heart - Pathways to Translation. To view the other articles in this section visit
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据